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ABSTRACT
Introduction: To investigate the effects of
eplerenone compared to observation in the
treatment of acute central serous chori-
oretinopathy (CSC).
Methods: Charts of consecutive patients with a
diagnosis of acute CSC (visual symptoms
\12 weeks) were reviewed. Included patients
were divided into a treatment group (treated
with eplerenone) and a control group (obser-
vation). Main outcome measures included
changes in best-corrected visual acuity (BCVA),
central macular thickness (CMT), height of
subretinal fluid (SRF) and subfoveal choroidal
thickness (CT) at 1 and 3 months in the two
groups.
Results: Fifteen eyes of 15 patients (2 female,
13 male) and 12 eyes of 12 patients (1 female, 11
male [p = 1.000]) were included in the treat-
ment and control groups, respectively. The
mean age was 44 ± 9 (30–65) and 47 ± 11 years
(28–66 years, p = 0.493), respectively. In the
treatment group, BCVA improved significantly
at 1 month (p = 0.018) and 3 months of follow-
up (p = 0.011), while a non-significant
improvement was seen in the control group. At
3 months, 12 of 15 eyes (80%) in the treatment
group demonstrated complete SRF resolution,
versus 3 of 12 eyes (25%) in the control group
(p = 0.007). In the treatment group, SRF and
CMT were significantly reduced at the 1-month
follow-up (p = 0.014, p = 0.028, respectively)
and the 3-month follow-up (p\0.001 for both
analyses), while in the control group the chan-
ges were not statistically significant. Eplerenone
was well tolerated in all patients.
Conclusion: Patients affected by acute CSC
treated with eplerenone achieved greater and
faster resolution of the disease compared to the
observation group. Eplerenone may represent
an attractive new first-line treatment option for
acute CSC.
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INTRODUCTION
Central serous chorioretinopathy (CSC) is a
common disorder that typically affects young
adult men, with an incidence of approximately
5.8 per 100,000 people [1]. Acute disease is
characterized by the presence of serous retinal
detachment and/or retinal pigment epithelial
(RPE) detachment located in the macular
region, leading to central vision loss, dyschro-
matopsia, central or paracentral scotoma,
metamorphopsia and/or micropsia. Acute CSC
is typically a benign disorder that resolves
spontaneously in 2–3 months [2]. Nevertheless,
approximately 30–50% of patients experience a
recurrence of the disease over the long term
[3, 4]. In addition, 5–10% of cases of unresolved
disease may progress to chronic CSC (also
known as diffuse retinal epitheliopathy), which
includes persistent serous retinal detachment,
associated with diffuse RPE alterations and, in
some cases, cystoid retinal degeneration or
pigment epithelium detachment [3]. In chronic
CSC, the persistent fluid accumulation leads to
progressive and irreversible damage to the
photoreceptors that may have a decisive effect
on visual prognosis [3, 5].
The pathogenesis of CSC is extremely com-
plex and still poor understood. Risk factors for
acute CSC include a stress-prone personality
(type A behavior), an increased sympathetic
activity, the use of systemic corticosteroid and
hypertension [6–8].
Recent investigations strongly support the
hypothesis that CSC is primarily characterized
by vascular deregulation in the choroid. In fact,
choroidal hyperpermeability changes have been
clearly shown using fluorescein angiography
(FA) and indocyanine green angiography
(ICGA) [9, 10], and increased choroidal thick-
ness has been demonstrated in both the affected
and contralateral eyes when measured with
optical coherence tomography (OCT) [11–13].
New insights into the pathogenesis of this
multifactorial disease have revealed that gluco-
corticoid and mineralocorticoid dysfunction is
also present [14–16]. In animal models, the
activation of choroidal mineralocorticoid
receptors was shown to cause choroidal
vasodilation and leakage; this phenomenon was
inhibited by mineralocorticoid receptor (MR)
antagonism [17]. Based on these findings,
researchers investigated the role of mineralo-
corticoid antagonists in the treatment of CSC,
reporting positive preliminary results [17–28].
Spironolactone and eplerenone are both oral-
specific MR antagonists approved for several
systemic disorders, and are commonly used for
treating hypertension and congestive heart
failure. However, spironolactone, although
effective, is associated with various unwanted
progestational and antiandrogenic side effects,
such as gynecomastia, impotence and abnormal
menstrual cycles, which can limit its use.
Eplerenone has a lower affinity for steroid
receptors (e.g. progesterone and androgen),
leading to higher tolerability and specificity.
Recent reports have highlighted the poten-
tial benefits of eplerenone in patients with CSC,
showing promising results in terms of gains in
best-corrected visual acuity (BCVA) and reduc-
tions in central macular thickness (CMT) on
OCT. However, to the best of our knowledge,
there are no data available concerning the
treatment of acute CSC with eplerenone com-
pared to observation. Therefore, the aim of this
study was to investigate the effects of epler-
enone in the treatment of acute CSC compared
to observation.
MATERIALS AND METHODS
We reviewed the charts of consecutive patients
with a diagnosis of acute CSC referred to the
Medical Retina and Imaging Division of San
Raffaele Hospital (Milan, Italy) and to the Fon-
dazioneG. B. Bietti-IRCCS (Rome, Italy) between
January 2016 and July 2017, treated with epler-
enone or with observation. All procedures per-
formed in studies involving human participants
were in accordance with the ethical standards of
the institutional research committee and with
the 1964 Helsinki declaration and its later
amendments or comparable ethical standards.
Informed consent was obtained from all indi-
vidual participants included in the study.
Patients were eligible for inclusion if they
were at least 18 years of age, with a diagnosis of
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acute CSC, defined by the presence of subretinal
fluid and visual symptoms for less than
12 weeks, and were experiencing an episode of
CSC for the first time. Exclusion criteria were
the presence of chronic CSC (duration of visual
symptoms more than 12 weeks) or recurrent
CSC (patients with a history of one or more
previous CSC attacks), presence of choroidal
neovascularization (CNV) identified by FA,
ICGA and/or OCT angiography (OCT-A), any
treatment for retinal disease (including intrav-
itreal injections, photodynamic therapy, laser
photocoagulation, vitrectomy), history of other
retinal disorders (including age-related macular
degeneration, choroidal neovascularization,
diabetic retinopathy, uveitis or pathologic
myopia) and the presence of any other systemic
condition for which eplerenone was con-
traindicated (such as severe renal, cardiac or
hepatic failure, pregnancy, baseline serum
potassium greater than 5.0 mEq/L, concomitant
administration of potassium-sparing diuretics,
potassium supplements, strong CYP3A4 inhibi-
tors, angiotensin-converting enzyme inhibitors
or angiotensin receptor blockers).
All patients who met the inclusion criteria
were assigned to either the treatment group
(treated with eplerenone) or the observation
group. All patients treated with eplerenone were
consecutively included at San Raffaele Hospital,
while all observed subjects were consecutively
included at the Fondazione G. B. Bietti-IRCCS.
The follow-up period was 3 months.
The patients in the treatment group were
treated with eplerenone 25 mg/day for 1 week
and then 50 mg/day for 11 weeks. Serum potas-
sium and creatinine assessment were performed
at baseline before starting treatment and
monthly during treatment. Eplerenone was dis-
continued in the case of increased serum potas-
siumor creatinine or in cases of drug intolerance.
At baseline, each patient underwent assess-
ment of BCVA on standard ETDRS charts, con-
verted into logarithm of the minimal angle of
resolution (logMAR) for statistical analysis,
along with comprehensive ophthalmological
examination and multimodal imaging by fun-
dus autofluorescence, FA, ICGA and spectral
domain-OCT (SD-OCT; Spectralis HRA?OCT
[Heidelberg Retina Angiograph ? OCT];
Heidelberg Engineering, Heidelberg, Germany)
and swept-source OCT-A (PLEX Elite 9000; Carl
Zeiss Meditec Inc., Dublin, CA, USA). Patients
included in the study were followed up at 1 and
3 months with BCVA, IOP, biomicroscopy, SD-
OCT and OCT-A examinations.
SD-OCT evaluation included CMT analysis
using macular thickness maps. Manual measure-
ment of subfoveal retinal fluid (SRF) height was
performed for eachcontrol,measuring thedistance
between the end of the outer segment and the
retinal pigment epithelium at the foveal center.
The subfoveal choroidal thickness (CT), defined as
the vertical distance between the hyper-reflective
line of Bruch’s membrane and the chorio-scleral
interface, was measured manually using an
enhanced-depth imaging (EDI) technique.
The main outcome measures included com-
parisons of BCVA, CMT, SRF and subfoveal CT
between the treatment and control groups and
at all time points. Safety analysis and treatment
tolerance were recorded at each visit.
Statistical Analysis
Statistical analyses were performed using SPSS
Statistics version 20 software (IBMCorp., Armonk,
NY, USA). Results of descriptive analyses were
expressed as means± standard deviations for
quantitative variables, and as counts and percent-
ages for categorical variables. Associationsbetween
categorical variables were analyzed using Fisher’s
exact test. The Gaussian distribution of continu-
ous variables was verified with the Kol-
mogorov–Smirnov test. Comparisons of age, CSC
duration, BCVA, CMT, SRF and subfoveal CT
between treatment and control groups were per-
formed using the Student independent samples
t test. Comparisons of BCVA, SRF, CMT and sub-
foveal CT between the three time points were
performed using repeated measures analysis of
variance (ANOVA) with Bonferroni correction for
post hoc analysis. In all analyses, p values\0.05
were considered statistically significant.
RESULTS
A total of 27 eyes of 27 white patients met the
inclusion criteria and were included in the
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study. Fifteen eyes of 15 patients (2 female, 13
male) were included in the treatment group,
while 12 eyes of 12 patients (1 female, 11 male
[p = 1.000]) were included in the control group.
The subjects of the two groups were similar in
age, with a mean age of 44 ± 9 years (range
30–65 years) and 47 ± 11 years (range 28–-
66 years, p = 0.493) for the treatment and con-
trol groups, respectively. No patients in either
group were affected by any condition that
might play a role in the development of CSC,
including medication use (such as steroids),
pregnancy or other systemic diseases (e.g.
endogenous hypercortisolism) related to the
disease pathogenesis. In particular, no included
patients were receiving any type of chronic
therapy.
At baseline, patients had been affected by
CSC for a mean of 6.6 ± 2.9 weeks (median 6;
range 1–11 weeks) and presented a leakage
point at ICGA. In accordance with the inclusion
criteria, no signs of CNV were revealed on OCT-
A or dye angiography. On structural SD-OCT, all
patients presented SRF (mean SRF,
180 ± 102 lm; range, 21–363 lm), and BCVA
was 0.14 ± 0.10 logMAR (range 0.0–0.4). As
reported in Table 1, no differences in CSC
duration, BCVA, CMT, SRF or subfoveal CT were
noted at baseline between the two groups.
In the treatment group, BCVA improved
significantly during the follow-up, from
0.15 ± 0.12 logMAR at baseline to 0.10 ± 0.11
logMAR after 1 month (p = 0.018), and to
0.06 ± 0.06 logMAR after 3 months (p = 0.011).
BCVA also improved in the control group,
although this was not statistically significant
(from 0.12 ± 0.06 logMAR at baseline to
0.09 ± 0.05 logMAR after 1 month [p = 0.246],
and to 0.08 ± 0.07 logMAR after 3 months
[p = 0.498]). However, no significant difference
was observed between the two groups in BCVA
at baseline or at the 1- or 3-month follow-up
(p = 0.337, p = 0.816 and p = 0.378,
respectively).
At the first follow-up visit after 1 month, 7 of
15 eyes (47%) in the treatment group demon-
strated complete SRF resolution on structural
SD-OCT, while only 1 of 12 eyes (8%) in the
control group achieved the same result
(p = 0.043; Figs. 1, 2). A significant difference
was also evident at the second follow-up visit,
after 3 months: 12 of 15 eyes (80%) in the
treatment group demonstrated complete SRF
resolution (Fig. 1), versus 3 of 12 eyes (25%) in
the control group (p = 0.007). In the treatment
group, SRF decreased significantly during the
follow-up (SRF: 188 ± 107 lm, 78 ± 85 lm
[p = 0.014] and 17 ± 50 lm [p\0.001] at base-
line and 1- and 3-month follow-up, respec-
tively), and CMT also decreased significantly,
from 426 ± 104 lm at baseline to 330 ± 81 lm
at 1-month follow-up (p = 0.028) and to
274 ± 60 lm at 3-month follow-up (p\0.001;
Table 2). In the control group, SRF decreased
slightly during follow-up, with no statistically
significant difference, and CMT did not change
significantly (Table 2). No significant difference
Table 1 Demographics and main clinical features of the
study population
Treatment
group
Control
group
P value
Eyes (patients), no. 15 (15) 12 (12)
Sex, no.
Male 13 11
Female 2 1 1.000a
Age, years
(mean ± SD)
44 ± 9 47 ± 11 0.493b
Duration of
symptoms, weeks
(mean ± SD)
6.9 ± 3.1 6.3 ± 2.8 0.645b
BCVA, logMAR
(mean ± SD)
0.15 ± 0.12 0.12 ± 0.06 0.337b
CMT, lm
(mean ± SD)
426 ± 104 409 ± 113 0.693b
SRF, lm
(mean ± SD)
188 ± 107 171 ± 100 0.679b
Subfoveal CT, lm
(mean ± SD)
436 ± 78 378 ± 76 0.064b
SD standard deviation, BCVA best-corrected visual acuity,
CMT central macular thickness, SRF subretinal ﬂuid, CT
choroidal thickness
a Fisher’s exact test, bStudent’s t test
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was observed between the two groups in SRF or
CMT at baseline or after 1 month (p = 0.679 and
p = 0.083 for SRF at baseline and 1-month fol-
low-up, respectively, and p = 0.693 and
p = 0.079 for CMT at baseline and 1-month
follow-up, respectively). However, a significant
difference in SRF and CMT was observed
between groups at 3 months (p = 0.002 and
p\0.001, respectively).
Subfoveal CT decreased significantly during
the follow-up in the treatment group (from
436 ± 78 lm at baseline to 418 ± 86 lm at
3-month follow-up [p = 0.019]), while no sig-
nificant decrease was found in the control
group (p = 1.000). Furthermore, no differences
were found in subfoveal CT between 15 patients
who achieved complete resolution of SRF and
12 patients who did not (p = 0.873, p = 0.607
and p = 0.970 at baseline and at 1- and 3-month
follow-up, respectively).
No serious ocular or systemic side effects
related to eplerenone treatment were recorded
during the follow-up.
DISCUSSION
Treatment of CSC remains challenging. Acute
CSC is generally a self-limiting disease, with
almost 25% of patients experiencing complete
resolution of symptoms in 3 months or less
without any treatment [29]. According to the
natural benign course of the disease, observa-
tion may be considered as a first line of therapy.
Fig. 1 Multimodal imaging evaluation of a patient
affected by acute CSC included in the treatment group.
At baseline, ﬂuorescein angiography (a) and indocyanine
green angiography (b) revealed a leakage point; 3 9 3 en
face optical coherence tomography (OCT) angiography of
choriocapillaris slab (c) showed no signs of choroidal
neovascularization; and structural OCT (d) revealed the
presence of subretinal ﬂuid and increased choroidal
thickness. At 1 month (e) and 3 months (f) after
eplerenone treatment, the complete absence of subretinal
ﬂuid was clearly visible on structural OCT
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Nevertheless, patients who do not achieve
spontaneous recovery can progress to chronic
disease, with persistent subretinal fluid, pro-
gressive RPE damage and irreversible visual
deterioration. In addition, since patients gen-
erally express a strong desire for faster resolu-
tion of symptoms, treatment is also necessary in
cases of acute self-limiting disease.
Focal laser photocoagulation targeted to the
leakage point has been used in the past to
reduce a unique and extrafoveal RPE leak [30].
Full or half-fluence photodynamic therapy
(PDT) still plays a key role in the treatment of
CSC in order to reduce choroidal hyperperme-
ability. Several studies have confirmed the effi-
cacy of PDT, showing a reduction in serous
retinal detachment and a decrease in choroidal
thickness, but the safety effects are still debated
over the long term [27–32]. Intravitreal anti-
vascular endothelial growth factor (VEGF)
agents have been given to reduce vascular per-
meability, although the exact role of VEGF in
the pathogenesis of CSC is still unclear [33].
Therefore, a specific treatment targeted to the
mechanism of choroidal dysfunction is still
lacking.
Previous studies have shown that over-acti-
vation of the MR pathway is involved in the
pathogenesis of CSC, related to an excess of
corticosteroids or MR hypersensitivity, based
on genetic or environmental predisposition
[17].
Fig. 2 Baseline multimodal imaging of a patient affected
by acute CSC included in the control group. At baseline,
ﬂuorescein angiography (a) and indocyanine green angiog-
raphy (b) revealed a leakage point; 3 9 3 en face optical
coherence tomography (OCT) angiography of choriocap-
illaris slab (c) showed no signs of choroidal
neovascularization; and structural OCT (d) revealed the
presence of subretinal ﬂuid and increased choroidal
thickness. At 1 month (e) and 3 months (f) after obser-
vation, no signiﬁcant differences in subfoveal ﬂuid were
observed at structural OCT
114 Ophthalmol Ther (2018) 7:109–118
The results of this study revealed that oral
eplerenone, acting on the MR pathway, was
more effective than observation in the treat-
ment of acute CSC. In fact, in the treatment
group, BCVA improved significantly at all time
points, while visual improvement was not sta-
tistically significant in the control group. The
results concerning changes in SRF and CMT
followed the same trend, with a significant
decrease at all follow-up visits in the treatment
group, while no statistically significant changes
were shown in the control group. With regard
to SRF resolution, at 1 month, 47% of the
patients in the treatment group demonstrated
complete reabsorption, compared to only 8% of
those in the control group. A significant differ-
ence was also evident at 3 months: 80% of
subjects in the treatment group demonstrated
complete SRF resolution, versus only 25% in the
control group.
In addition, subfoveal CT decreased signifi-
cantly during follow-up in the treatment group,
while no significant changes were found in the
control group. These results strongly support
the theory that eplerenone has a meaningful
effect against the inappropriate activation of
the mineralocorticoid receptors found in the
choroidal vasculature of patients with CSC.
The percentage of patients achieving resolu-
tion of the disease varies in the literature,
according to the main outcome measures con-
sidered and the different populations
[18, 21, 23, 24, 28]. In the study by Ghadiali
et al. [19], the efficacy of both eplerenone and
spironolactone was assessed in eyes with pre-
dominantly chronic disease. Even though a
significant visual improvement was achieved in
all patients, CMT and subfoveal CT showed no
significant change. More than 90% of eyes
exhibited chronic CSC, and about half of the
patients enrolled had exudative CSC without
subretinal fluid, suggesting that both MR
antagonists might be less effective in the
chronic form of the disease.
However, to the best of our knowledge, no
study has analyzed the effects of eplerenone in
acute CSC. Sun et al. [29] investigated the
effects of spironolactone versus observation in
patients with acute CSC. Similar to our study,
they found that complete resolution of SRF was
Table 2 Main changes in clinical parameters from baseline at each follow-up in all data
Baseline 1-month examination p value 3-month examination p value
BCVA, logMAR (mean ± SD)
Treatment group 0.15 ± 0.12 0.10 ± 0.11 0.018a 0.06 ± 0.06 0.011a
Control group 0.12 ± 0.06 0.09 ± 0.05 0.246a 0.08 ± 0.07 0.498a
SRF, lm (mean ± SD)
Treatment group 188 ± 107 78 ± 85 0.014a 17 ± 50 \0.001a
Control group 171 ± 101 147 ± 115 0.431a 134 ± 118 0.453a
CMT, lm (mean ± SD)
Treatment group 426 ± 104 330 ± 81 0.028a 274 ± 60 p\0.001a
Control group 409 ± 113 396 ± 107 1.000a 409 ± 103 1.000a
Subfoveal CT, lm (mean ± SD)
Treatment group 436 ± 78 429 ± 88 1.000a 418 ± 86 0.019a
Control group 378 ± 76 381 ± 63 1.000a 384 ± 83 1.000a
BCVA best-corrected visual acuity, SD standard deviation, SRF subretinal ﬂuid, CMT central macular thickness, CT
choroidal thickness
a Analysis of variance (ANOVA) with Bonferroni correction for post hoc analysis
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achieved at 2 months in 56% of treated
patients, compared to 8% of patients in the
control group. The mean CMT and SRF
decreased significantly at each visit in both
groups, and BCVA improved in both groups at
2 months. In accord with our results, they
observed that the subfoveal CT decreased sig-
nificantly in the treatment group at 2 months,
while the change from baseline was not signif-
icant in the control group. In addition, the
authors reported that none of the patients in
the treatment group developed any side effects
related to the use of spironolactone, likely
because of the short period of treatment.
Although eplerenone has a lower affinity for the
MR and a theoretically less effective action than
spironolactone, our results are in line with
those of Sun et al.
We acknowledge that our study has several
limitations, primarily related to the small sam-
ple and short follow-up duration. Further ran-
domized placebo-controlled clinical studies are
needed to increase our knowledge in the treat-
ment of such complex disease.
CONCLUSIONS
This study showed that patients affected by
acute CSC treated with eplerenone achieved
higher and faster resolution of the disease than
those with observation. Although this study has
some limitations, our results show that epler-
enone is an effective non-invasive treatment
option for acute CSC, with a good safety profile,
confirmed by regular laboratory checks. In
conclusion, eplerenone may represent an
attractive new first-line treatment option for
acute CSC.
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